OBJECTIVE: To compare dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and T2-weighted imaging (T2WI) at 3.0T for detection of prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS: Patients with elevated prostate-specific antigen underwent T2WI and DCE-MRI prior to prostate needle biopsy. The sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of T2WI and DCE-MRI to diagnose prostate cancer were evaluated. The relationship between Gleason score and prostate cancer detection by DCE-MRI was evaluated.
RESULTS: Prostate adenocarcinoma was histopathologically confirmed in 44/75 patients. DCE-MRI had significantly higher sensitivity, accuracy and NPV than T2WI. The detection rate of prostate cancer by DCE-MRI was significantly better for tumours with Gleason score 7-9 than for those Gleason score 4-6.
CONCLUSION: DCE-MRI at 3.0T can significantly improve prostate cancer detection using simple visual diagnostic criteria, compared with T2WI.
Zhang X, Quan X, Lu S, Huang F, Yang J, Chan Q, Lin T. Are you the author?
Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China; Philips Healthcare, Hong Kong, China.
Reference: J Int Med Res. 2014 Aug 4. pii: 0300060514541827.